Depression Johnson & Johnson

FDA approves Johnson & Johnson's nasal spray for depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

Gizmodo · 3h

Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

Popular Science · 13h

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

19hon MSN

FDA Approves Nasal Spray for Depression

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA approves Johnson & Johnson's nasal spray for depression

Trending now